GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Exelixis EXEL · USD

Health Care · US listing · 🇺🇸 United States

Compare

71.74

+3.12%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$2.32bn

FY2016FY2025

Net income

$782.6m

FY2016FY2025

Free cash flow

$844.3m

FY2016FY2025

Shareholders' equity

$2.16bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$2.32bn$2.17bn$1.83bn$1.61bn$1.43bn$987.5m$967.8m$853.8m$452.5m$191.5m
Gross profit$2.24bn$2.09bn$1.76bn$1.55bn$1.38bn$951.3m$934.7m$827.5m$437.4m$184.9m
Research and development$825.0m$910.4m$1.04bn$891.8m$693.7m$547.9m$337.0m$182.3m$112.2m$96.0m
Operating income$872.2m$604.6m$170.9m$201.5m$286.7m$110.1m$369.5m$438.9m$165.9m−$28.1m
Net income$782.6m$521.3m$207.8m$182.3m$231.1m$111.8m$321.0m$690.1m$154.2m−$70.2m
Diluted earnings per share2.781.850.660.560.710.351.022.210.49-0.23

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$2.84bn$2.95bn$2.94bn$3.07bn$2.62bn$2.14bn$1.89bn$1.42bn$655.3m$597.5m
Cash and short-term investments$1.06bn$1.11bn$995.3m$1.31bn$1.47bn$1.21bn$852.2m$693.3m$387.8m$419.8m
Total liabilities$683.1m$703.5m$678.4m$583.1m$405.6m$258.2m$199.7m$134.8m$370.3m$508.2m
Debt—$25.0m$25.7m————$56.9m$72.0m$189.1m
Shareholders' equity$2.16bn$2.24bn$2.26bn$2.49bn$2.21bn$1.88bn$1.69bn$1.29bn$285.0m$89.3m
Shares outstanding282m282m313m323m323m320m315m312m313m301m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$884.3m$700.0m$333.3m$362.6m$400.8m$209.0m$527.0m$415.7m$165.6m$206.3m
Capital spending−$39.9m−$66.2m−$163.0m−$138.5m−$64.2m−$30.3m−$12.8m−$33.3m−$21.1m−$1.7m
Free cash flow$844.3m$633.8m$170.4m$224.2m$336.6m$178.6m$514.1m$382.4m$144.5m$204.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Oct 2025Jul 2025Apr 2025Dec 2024Sept 2024
Revenue$628.7m$610.8m$598.7m$597.8m$568.3m$555.4m$566.8m$539.5m
Gross profit$608.0m$590.9m$572.2m$579.2m$548.8m$536.3m$546.8m$522.2m
Operating income$248.4m$251.3m$235.2m$256.4m$213.6m$186.9m$163.2m$136.1m
Net income$212.1m$210.5m$244.5m$193.6m$184.8m$159.6m$139.9m$118.0m
Diluted earnings per share0.820.810.870.700.650.550.500.42
Cash from operations$307.0m$251.0m$333.0m$290.0m$48.0m$211.0m$240.0m$271.0m
Capital spending−$2.0m−$2.0m−$1.0m−$1.0m−$3.0m−$22.0m−$13.0m−$9.0m
Free cash flow$305.0m$249.0m$332.0m$289.0m$45.0m$189.0m$227.0m$262.0m
Total assets$2.49bn$2.59bn$2.84bn$2.82bn$2.68bn$2.84bn$2.95bn$2.96bn
Cash and short-term investments$839.4m$777.2m$1.06bn$988.5m$791.1m$1.03bn$1.11bn$1.19bn
Debt———————−$3.3m
Shareholders' equity$1.84bn$1.94bn$2.16bn$2.16bn$2.03bn$2.13bn$2.24bn$2.28bn

Financial ratios

Data as of 5 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017FY2016FY2015FY2014FY2013
Gross margin96.4%96.5%96.0%96.4%96.3%96.3%——————
Operating margin37.6%27.9%9.3%12.5%20.0%11.1%——————
Net margin33.7%24.0%11.4%11.3%16.1%11.3%——————
Return on equity36.2%23.2%9.2%7.3%10.5%5.9%——————
Return on assets27.5%17.7%7.1%5.9%8.8%5.2%——————
Free cash flow yield5.6%4.7%2.7%2.7%2.5%1.3%——————
Revenue growth7.0%18.5%13.6%12.3%45.3%2.0%——————
Earnings growth50.1%150.9%14.0%-21.1%106.7%-65.2%——————
Current ratio3.56x3.63x3.34x4.99x5.43x7.06x——————
Debt to equity—0.01x0.01x0.01x0.00x0.00x0.00x—————
Equity ratio76.0%76.1%76.9%81.0%84.5%87.9%——————
Interest coverage———3.75x———19.12x-0.85x-2.98x-5.43x-4.40x
R&D as a share of sales35.6%42.0%57.0%55.4%48.3%55.5%——————
Buybacks as a share of market value-0.0%10.0%3.2%-0.0%-1.1%-1.4%——————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.9%18.6%51.2%
Operating income63.0%51.3%—
Net income62.5%47.6%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin96.4%96.3%96.3%96.4%
Operating margin32.9%23.3%21.7%23.9%
Net margin29.0%21.4%19.7%23.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings15.818.036.128.425.657.417.38.961.8-64.0
Price to sales5.34.34.13.24.16.55.77.221.123.5

Market value over time

30 Nov 2016 to 2 Oct 2026, in USD

$4.34bn$15.16bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return26%41%54%-17%-7%8%1%-34%69%202%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.